Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

NCT00041652 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Colon Cancer
Rectal Cancer
Colorectal Neoplasms
Colorectal Carcinoma
Breast Cancer
Breast Neoplasms

Interventions

DRUG: hMN14 (labetuzumab)

Sponsor

Gilead Sciences